|

New Serum Biomarkers for Monitoring Early Diagnosis of Ovarian Cancer Recurrence

RECRUITINGSponsored by Peking Union Medical College Hospital
Actively Recruiting
SponsorPeking Union Medical College Hospital
Started2022-03-03
Est. completion2024-03-03
Eligibility
Age20 Years – 70 Years
SexFEMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05410028

Summary

In this study, mass spectrometry was used to analyze immune inflammation-related protein complexes, post-translational modified glycopeptide omics and tumor-related metabolomics in serum, respectively, in order to find potential metabolic small molecule biomarkers or marker profiles that can be used for early diagnosis of cancer recurrence.

Eligibility

Age: 20 Years – 70 YearsSex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

* Female
* A diagnosed patient with epithelial ovarian cancer
* Age ≤ 70

Exclusion Criteria:

* Male
* Suffering from other malignant tumors
* Non-compliant patient
* Age above 70

Conditions2

CancerOvarian Cancer

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.